Stock Financial Ratios, Dividends, Split History

NATH / Nathan's Famous, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price97.75
Volume6,700.00
Market Cap ($M)409.25
Enterprise Value ($M)496.67
Book Value ($M)-84.57
Book Value / Share-20.21
Price / Book-4.84
NCAV ($M)-92.95
NCAV / Share-22.21
Price / NCAV-4.40
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 4,221,000
Weighted Average Number Of Shares Outstanding Basic 4,181,000
Common Shares Outstanding 4,184,549
Common Stock Shares Outstanding 4,184,549
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)-0.04
Balance Sheet (mrq) ($M)
Assets80.09
Liabilities164.66
Quick Ratio3.96
Current Ratio3.98
Income Statement (mra) ($M)
Licenses Revenue0.00
Sales Revenue Goods Net0.00
Revenues104,201,000.00
Franchise Revenue0.00
Operating Income27.10
Net Income2.63
Earnings Per Share Basic0.63
Earnings Per Share Diluted0.62
Cash Flow Statement (mra) ($M)
Cash From Operations18.86
Cash from Investing-0.55
Cash from Financing-0.55
Identifiers and Descriptors
CUSIP632347100
Central Index Key (CIK)69733

Split History

Stock splits are used by Nathan's Famous, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

The 10 Best Stocks to Invest In Right Now | InvestorPlace

2018-06-25 investorplace
It’s a different market than it was at the beginning of 2018. Volatility has returned, even if it remains modest relative to historical levels. Big names like Procter & Gamble (NYSE:PG) and Walmart (NYSE:WMT), among others, have seen precipitous share price declines after record highs. (565-1)

Pass On Nathan's Famous For Now

2018-06-11 seekingalpha
NATH is up 1/3 in the last three months and trades close to the upper limit of its historical range across P/S, P/CF, and EV/EBITDA metrics. (2-0)

Nathan’s Famous, Inc. Stock Pops on Q4 Earnings Results

2018-06-09 investorplace
Nathan’s Famous, Inc. (NASDAQ:NATH) reported its latest quarterly earnings results early Friday, posting revenue increases but an earnings decline. (2-0)

The 10 Best Stocks to Invest In Right Now

2018-04-09 investorplace
It’s a different market than it was at the end of January. Volatility has returned, even if it remains modest relative to historical levels. Big names like Procter & Gamble Co (NYSE:PG) and Walmart Inc (NYSE:WMT), among others, have seen precipitous share price declines after record highs. (564-0)

The 10 Best Stocks to Invest In Right Now

2018-03-15 investorplace
It’s a different market than it was just two months ago. Volatility has returned, even if it remains modest relative to historical levels. Big names like Procter & Gamble Co (NYSE:PG) and Walmart Inc (NYSE:WMT), among others, have seen precipitous share price declines just in the past few weeks. (564-1)

CUSIP: 632347100